Drugmaker Group Sets Lobbying Record
From Bloomberg: The Pharmaceutical Research and Manufacturers of America (PhRMA) spent $9.96 million on federal lobbying in the first three months of 2018, representing an...
PhRMA Ups Lobbying by 30 Percent This Year
From The Hill: The pharmaceutical industry's top trade group, the Pharmaceutical Research and Manufacturers of America (PhRMA), has increased its federal lobbying expenditures by 30...
SCOTUS Declines Risperdal Appeal, J&J to Pay $124 M
On Monday, the US Supreme Court declined to hear Johnson and Johnson’s final appeal, forcing the company to pay $124 million for the deceptive marketing of the antipsychotic Risperdal. In 2011, South Carolina ordered the company to pay $327 million for pursuing “profits-at-all-costs” in its efforts to persuade doctors to prescribe their drug, but the fine was lowered to $136 million last year. The company had hoped to argue that the remaining penalties constituted an “excessive fine” and was supported by PhRMA, the Washington Legal Foundation, the Cato Institute and the Chamber of Commerce.